Loading...
Market
Will zanidatamab-hrii be approved for additional indications by the end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements or Jazz Pharmaceuticals' press releases
Story
FDA Approves Jazz's Zanidatamab for HER2+ Biliary Cancer with 52% Response Rate
Nov 21, 2024, 12:36 AM
The U.S. Food and Drug Administration (FDA) has approved a new drug, zanidatamab-hrii (Ziihera), developed by Jazz Pharmaceuticals, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval marks a significant advancement in the treatment of this specific cancer type, with the drug showing a 52% response rate and a median duration of response of 14.9 months.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%